RxDoctor Payments DataLook up a doctor →

Henry Townsend, MD

Rheumatology · Plano, TXNPI 1922114354

Payments from drug & device makers

$738,234in general payments, 2019–2025

Across 1,977 payments — averaging $373.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$236K
  • Amgen$236K
  • Johnson & Johnson$121K
  • Janssen Scientific Affairs, LLC$59K
  • Pfizer$29K
  • E.r. Squibb & Sons, L.L.C.$19K
  • plus $38K from 37 others

What the payments were for

  • Consulting fees$85,77512%
  • Speaking & faculty fees$509,01769%
  • Travel & lodging$101,61114%
  • Food & beverage$41,3646%
  • Education$4670%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$738,234 in reported general payments places this provider in the 90th percentile of 512 rheumatology providers in Texas.

See all rheumatology providers in Texas

Medicare billing

Part B allowed, 2024
$562,707
Medicare patients
153
Services billed
55,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept79$613,944
Humira(Cf) PenAdalimumab43$319,120
StelaraUstekinumab21$283,219
RinvoqUpadacitinib32$198,796
XeljanzTofacitinib Citrate32$198,094
EnbrelEtanercept23$167,036
TremfyaGuselkumab11$147,770
Simponi AriaGolimumab15$140,210
Xeljanz XrTofacitinib Citrate20$109,945
Cimzia (2 Pack)Certolizumab Pegol18$109,030
ActemraTocilizumab20$86,908
OrenciaAbatacept/Maltose19$74,229
Hydroxychloroquine Sulfate310$19,755
MethotrexateMethotrexate Sodium523$15,779
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen375$7,182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara, Tremfya, Simponi Aria$121,141$571,19947 claims
AbbVieRinvoq$236,450$198,79632 claims
PfizerXeljanz$29,051$198,09432 claims
AmgenEnbrel$235,989$167,03623 claims
UCB, Inc.Cimzia (2 Pack)$14,502$109,03018 claims
E.r. Squibb & Sons, L.L.C.Orencia$18,952$74,22919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 512 rheumatology providers in Texas.

Other rheumatology in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →